ID   KPCI_HUMAN              Reviewed;         596 AA.
AC   P41743; Q8WW06;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2009, sequence version 2.
DT   05-OCT-2010, entry version 121.
DE   RecName: Full=Protein kinase C iota type;
DE            EC=2.7.11.13;
DE   AltName: Full=Atypical protein kinase C-lambda/iota;
DE            Short=PRKC-lambda/iota;
DE            Short=aPKC-lambda/iota;
DE   AltName: Full=nPKC-iota;
GN   Name=PRKCI; Synonyms=DXS1179E;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   MEDLINE=94043266; PubMed=8226978;
RA   Selbie L.A., Schmitz-Peiffer C., Sheng Y., Biden T.J.;
RT   "Molecular cloning and characterization of PKC iota, an atypical
RT   isoform of protein kinase C derived from insulin-secreting cells.";
RL   J. Biol. Chem. 268:24296-24302(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Teratocarcinoma;
RX   MEDLINE=95331807; PubMed=7607695; DOI=10.1016/0888-7543(95)80190-W;
RA   Mazzarella R., Ciccodicola A., Esposito T., Arcucci A., Migliaccio C.,
RA   Jones C., Schlessinger D., D'Urso M., D'Esposito M.;
RT   "Human protein kinase C iota gene (PRKCI) is closely linked to the BTK
RT   gene in Xq21.3.";
RL   Genomics 26:629-631(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   INTERACTION WITH SMG1, AND ENZYME REGULATION.
RX   MEDLINE=96104559; PubMed=8524286;
RA   Diaz-Meco M.T., Municio M.M., Sanchez P., Lozano J., Moscat J.;
RT   "Lambda-interacting protein, a novel protein that specifically
RT   interacts with the zinc finger domain of the atypical protein kinase C
RT   isotype lambda/iota and stimulates its kinase activity in vitro and in
RT   vivo.";
RL   Mol. Cell. Biol. 16:105-114(1996).
RN   [5]
RP   INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION.
RX   PubMed=9566925;
RA   Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.;
RT   "Localization of atypical protein kinase C isoforms into lysosome-
RT   targeted endosomes through interaction with p62.";
RL   Mol. Cell. Biol. 18:3069-3080(1998).
RN   [6]
RP   INTERACTION WITH SQSTM1 AND IKBKB, AND FUNCTION.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [7]
RP   INTERACTION WITH PARD6A; PARD6B AND PARD6G, AND SUBUNIT OF A COMPLEX
RP   CONTAINING PARD6B AND CDC42/RAC1.
RX   MEDLINE=21160560; PubMed=11260256;
RX   DOI=10.1046/j.1365-2443.2001.00404.x;
RA   Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.;
RT   "Human homologues of the Caenorhabditis elegans cell polarity protein
RT   PAR6 as an adaptor that links the small GTPases Rac and Cdc42 to
RT   atypical protein kinase C.";
RL   Genes Cells 6:107-119(2001).
RN   [8]
RP   INTERACTION WITH PARD3 AND PARD6B IN THE TERNARY AKPC/PAR3/PAR6
RP   COMPLEX.
RX   MEDLINE=21157398; PubMed=11257119; DOI=10.1083/jcb.152.6.1183;
RA   Suzuki A., Yamanaka T., Hirose T., Manabe N., Mizuno K., Shimizu M.,
RA   Akimoto K., Izumi Y., Ohnishi T., Ohno S.;
RT   "Atypical protein kinase C is involved in the evolutionarily conserved
RT   par protein complex and plays a critical role in establishing
RT   epithelia-specific junctional structures.";
RL   J. Cell Biol. 152:1183-1196(2001).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH GAPDH.
RX   PubMed=11724794; DOI=10.1074/jbc.M109744200;
RA   Tisdale E.J.;
RT   "Glyceraldehyde-3-phosphate dehydrogenase is phosphorylated by protein
RT   kinase Ciota /lambda and plays a role in microtubule dynamics in the
RT   early secretory pathway.";
RL   J. Biol. Chem. 277:3334-3341(2002).
RN   [10]
RP   PHOSPHORYLATION AT TYR-265; TYR-280 AND TYR-334, AND MUTAGENESIS OF
RP   TYR-265; TYR-280 AND TYR-334.
RX   PubMed=11713277; DOI=10.1128/MCB.21.24.8414-8427.2001;
RA   Wooten M.W., Vandenplas M.L., Seibenhener M.L., Geetha T.,
RA   Diaz-Meco M.T.;
RT   "Nerve growth factor stimulates multisite tyrosine phosphorylation and
RT   activation of the atypical protein kinase C's via a src kinase
RT   pathway.";
RL   Mol. Cell. Biol. 21:8414-8427(2001).
RN   [11]
RP   INTERACTION WITH KPNB1, SUBCELLULAR LOCATION, PHOSPHORYLATION AT
RP   TYR-265, AND MUTAGENESIS OF TYR-265.
RX   PubMed=11891849; DOI=10.1002/jcb.10101.abs;
RA   White W.O., Seibenhener M.L., Wooten M.W.;
RT   "Phosphorylation of tyrosine 256 facilitates nuclear import of
RT   atypical protein kinase C.";
RL   J. Cell. Biochem. 85:42-53(2002).
RN   [12]
RP   INTERACTION WITH ADAP1.
RX   MEDLINE=22774667; PubMed=12893243; DOI=10.1016/S0006-291X(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms
RT   of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [13]
RP   INTERACTION WITH PARD6B/PAR-6 AND LLGL1.
RX   PubMed=12725730; DOI=10.1016/S0960-9822(03)00244-6;
RA   Yamanaka T., Horikoshi Y., Sugiyama Y., Ishiyama C., Suzuki A.,
RA   Hirose T., Iwamatsu A., Shinohara A., Ohno S.;
RT   "Mammalian Lgl forms a protein complex with PAR-6 and aPKC
RT   independently of PAR-3 to regulate epithelial cell polarity.";
RL   Curr. Biol. 13:734-743(2003).
RN   [14]
RP   INTERACTION WITH RAB2A.
RX   PubMed=14570876; DOI=10.1074/jbc.M309343200;
RA   Tisdale E.J.;
RT   "Rab2 interacts directly with atypical protein kinase C (aPKC)
RT   iota/lambda and inhibits aPKCiota/lambda-dependent glyceraldehyde-3-
RT   phosphate dehydrogenase phosphorylation.";
RL   J. Biol. Chem. 278:52524-52530(2003).
RN   [15]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15994303; DOI=10.1074/jbc.M505402200;
RA   Regala R.P., Weems C., Jamieson L., Copland J.A., Thompson E.A.,
RA   Fields A.P.;
RT   "Atypical protein kinase Ciota plays a critical role in human lung
RT   cancer cell growth and tumorigenicity.";
RL   J. Biol. Chem. 280:31109-31115(2005).
RN   [16]
RP   INTERACTION WITH CDK7, AND SUBCELLULAR LOCATION.
RX   PubMed=15695176; DOI=10.1016/j.tice.2004.10.004;
RA   Bicaku E., Patel R., Acevedo-Duncan M.;
RT   "Cyclin-dependent kinase activating kinase/Cdk7 co-localizes with PKC-
RT   iota in human glioma cells.";
RL   Tissue Cell 37:53-58(2005).
RN   [17]
RP   INTERACTION WITH RAB2A AND GADPH, PHOSPHORYLATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16452474; DOI=10.1074/jbc.M513031200;
RA   Tisdale E.J., Artalejo C.R.;
RT   "Src-dependent aprotein kinase C iota/lambda (aPKCiota/lambda)
RT   tyrosine phosphorylation is required for aPKCiota/lambda association
RT   with Rab2 and glyceraldehyde-3-phosphate dehydrogenase on pre-golgi
RT   intermediates.";
RL   J. Biol. Chem. 281:8436-8442(2006).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-412, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [20]
RP   STRUCTURE BY NMR OF 25-108, INTERACTION WITH SQSTM1 AND MAP2K5, AND
RP   MUTAGENESIS OF LYS-29 AND ASP-72.
RX   PubMed=15143057; DOI=10.1074/jbc.M403092200;
RA   Hirano Y., Yoshinaga S., Ogura K., Yokochi M., Noda Y., Sumimoto H.,
RA   Inagaki F.;
RT   "Solution structure of atypical protein kinase C PB1 domain and its
RT   mode of interaction with ZIP/p62 and MEK5.";
RL   J. Biol. Chem. 279:31883-31890(2004).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 25-108 IN COMPLEX WITH
RP   PARD6A, AND MUTAGENESIS OF ASP-72; GLU-85 AND ARG-91.
RX   PubMed=15590654; DOI=10.1074/jbc.M409823200;
RA   Hirano Y., Yoshinaga S., Takeya R., Suzuki N.N., Horiuchi M.,
RA   Kohjima M., Sumimoto H., Inagaki F.;
RT   "Structure of a cell polarity regulator, a complex between atypical
RT   PKC and Par6 PB1 domains.";
RL   J. Biol. Chem. 280:9653-9661(2005).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 233-596, MASS SPECTROMETRY,
RP   AND PHOSPHORYLATION AT THR-412 AND THR-564.
RX   PubMed=16125198; DOI=10.1016/j.jmb.2005.07.060;
RA   Messerschmidt A., Macieira S., Velarde M., Baedeker M., Benda C.,
RA   Jestel A., Brandstetter H., Neuefeind T., Blaesse M.;
RT   "Crystal structure of the catalytic domain of human atypical protein
RT   kinase C-iota reveals interaction mode of phosphorylation site in turn
RT   motif.";
RL   J. Mol. Biol. 352:918-931(2005).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-118 AND CYS-130.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium-independent, phospholipid-dependent, serine- and
CC       threonine-specific kinase. May play a role in the secretory
CC       response to nutrients. Involved in cell polarization processes and
CC       the formation of epithelial tight junctions. Implicated in the
CC       activation of several signaling pathways including Ras, c-Src and
CC       NF-kappa-B pathways. Functions in both pro- and anti-apoptotic
CC       pathways. Functions in the RAC1/ERK signaling required for
CC       transformed growth. Plays a role in microtubule dynamics through
CC       interaction with RAB2A and GAPDH and recruitment to vesicular
CC       tubular clusters (VTCs).
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Might be a target for novel lipid activators
CC       that are elevated during nutrient-stimulated insulin secretion.
CC       Two specific sites, Thr-412 (activation loop of the kinase domain)
CC       and Thr-564 (turn motif), need to be phosphorylated for its full
CC       activation (By similarity). Atypical PCKs are not regulated by
CC       diacylglycerol, phorbol esters nor calcium ions.
CC   -!- SUBUNIT: Forms a complex with SQSTM1 and MP2K5 (By similarity).
CC       Interacts directly with SQSTM1 (Probable). Interacts with IKBKB.
CC       Interacts with PARD6A, PARD6B and PARD6G. Part of a quaternary
CC       complex containing aPKC, PARD3, a PARD6 protein (PARD6A, PARD6B or
CC       PARD6G) and a GTPase protein (CDC42 or RAC1). Part of a complex
CC       with LLGL1 and PARD6B. Interacts with ADAP1/CENTA1. Interaction
CC       with SMG1, through the ZN-finger domain, activates the kinase
CC       activity. Interacts with CDK7. Forms a complex with RAB2A and
CC       GAPDH involved in recruitment onto the membrane of vesicular
CC       tubular clusters (VTCs).
CC   -!- INTERACTION:
CC       P60953:CDC42; NbExp=1; IntAct=EBI-286199, EBI-81752;
CC       P10040:crb (xeno); NbExp=1; IntAct=EBI-286199, EBI-672928;
CC       Q96L34:MARK4; NbExp=1; IntAct=EBI-286199, EBI-302319;
CC       Q8TEW0:PARD3; NbExp=1; IntAct=EBI-286199, EBI-81968;
CC       Q9NPB6:PARD6A; NbExp=4; IntAct=EBI-286199, EBI-81876;
CC       Q9BYG5:PARD6B; NbExp=2; IntAct=EBI-286199, EBI-295391;
CC       Q9BYG4:PARD6G; NbExp=1; IntAct=EBI-286199, EBI-295417;
CC       Q8ND90:PNMA1; NbExp=1; IntAct=EBI-286199, EBI-302345;
CC       Q04917:YWHAH; NbExp=1; IntAct=EBI-286199, EBI-306940;
CC       P63104:YWHAZ; NbExp=1; IntAct=EBI-286199, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane. Endosome. Nucleus.
CC       Note=Transported into the endosome through interaction with
CC       SQSTM1/p62. After phosphorylation by cSrc, transported into the
CC       nucleus through interaction with KPNB1. Colocalizes with CDK7 in
CC       the cytoplasm and nucleus. Vesicular tubular clusters. Transported
CC       to VTCs through interaction with RAB2A.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in lung and brain, but
CC       also expressed at lower levels in many tissues including
CC       pancreatic islets. Highly expressed in non-small cell lung
CC       cancers.
CC   -!- DOMAIN: The OPR domain mediates interaction with SQSTM1 (By
CC       similarity).
CC   -!- DOMAIN: The C1 domain does not bind diacylglycerol (DAG).
CC   -!- PTM: On neuronal growth factor (NGF) stimulation, phosphorylated
CC       by Src on Tyr-265, Tyr-280 and Tyr-334. Phosphorylation on Tyr-265
CC       facilitates binding to KPNB1/importin-beta regulating entry of
CC       PRKCI into the nucleus. Phosphorylation on Tyr-334 is important
CC       for NF-kappa-B stimulation.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily.
CC   -!- SIMILARITY: Contains 1 AGC-kinase C-terminal domain.
CC   -!- SIMILARITY: Contains 1 OPR domain.
CC   -!- SIMILARITY: Contains 1 phorbol-ester/DAG-type zinc finger.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA60171.1; Type=Erroneous initiation;
CC       Sequence=AAB17011.1; Type=Erroneous initiation;
CC       Sequence=AAH22016.3; Type=Erroneous initiation;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L18964; AAA60171.1; ALT_INIT; mRNA.
DR   EMBL; L33881; AAB17011.1; ALT_INIT; mRNA.
DR   EMBL; BC022016; AAH22016.3; ALT_INIT; mRNA.
DR   IPI; IPI00016639; -.
DR   PIR; A49509; A49509.
DR   RefSeq; NP_002731.4; -.
DR   UniGene; Hs.478199; -.
DR   PDB; 1VD2; NMR; -; A=25-108.
DR   PDB; 1WMH; X-ray; 1.50 A; A=25-108.
DR   PDB; 1ZRZ; X-ray; 3.00 A; A=233-596.
DR   PDB; 3A8W; X-ray; 2.10 A; A/B=249-588.
DR   PDB; 3A8X; X-ray; 2.00 A; A/B=249-588.
DR   PDBsum; 1VD2; -.
DR   PDBsum; 1WMH; -.
DR   PDBsum; 1ZRZ; -.
DR   PDBsum; 3A8W; -.
DR   PDBsum; 3A8X; -.
DR   ProteinModelPortal; P41743; -.
DR   IntAct; P41743; 56.
DR   MINT; MINT-5004219; -.
DR   STRING; P41743; -.
DR   PhosphoSite; P41743; -.
DR   PRIDE; P41743; -.
DR   Ensembl; ENST00000295797; ENSP00000295797; ENSG00000163558.
DR   GeneID; 5584; -.
DR   KEGG; hsa:5584; -.
DR   UCSC; uc003fgs.2; human.
DR   CTD; 5584; -.
DR   GeneCards; GC03P169940; -.
DR   H-InvDB; HIX0017930; -.
DR   HGNC; HGNC:9404; PRKCI.
DR   HPA; HPA026574; -.
DR   MIM; 600539; gene.
DR   PharmGKB; PA33768; -.
DR   eggNOG; prNOG08649; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P41743; -.
DR   OMA; KGDIMIT; -.
DR   OrthoDB; EOG93N9ZG; -.
DR   BRENDA; 2.7.11.13; 247.
DR   Pathway_Interaction_DB; il1pathway; IL1-mediated signaling events.
DR   Pathway_Interaction_DB; insulin_pathway; Insulin Pathway.
DR   Pathway_Interaction_DB; insulin_glucose_pathway; Insulin-mediated glucose transport.
DR   Pathway_Interaction_DB; trkrpathway; Neurotrophic factor-mediated Trk receptor signaling.
DR   Pathway_Interaction_DB; p75ntrpathway; p75(NTR)-mediated signaling.
DR   Pathway_Interaction_DB; tnfpathway; TNF receptor signaling pathway.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_20676; Cell junction organization.
DR   NextBio; 21656; -.
DR   ArrayExpress; P41743; -.
DR   Bgee; P41743; -.
DR   CleanEx; HS_PRKCI; -.
DR   Genevestigator; P41743; -.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000133; C:polarisome; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; TAS:UniProtKB.
DR   GO; GO:0005543; F:phospholipid binding; IDA:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; ISS:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006916; P:anti-apoptosis; EXP:Reactome.
DR   GO; GO:0045216; P:cell-cell junction organization; IMP:UniProtKB.
DR   GO; GO:0016044; P:cellular membrane organization; NAS:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:BHF-UCL.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial ...; TAS:UniProtKB.
DR   GO; GO:0090004; P:positive regulation of establishment of pro...; ISS:BHF-UCL.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISS:BHF-UCL.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; IDA:UniProtKB.
DR   GO; GO:0006612; P:protein targeting to membrane; NAS:UniProtKB.
DR   GO; GO:0046903; P:secretion; NAS:UniProtKB.
DR   GO; GO:0016192; P:vesicle-mediated transport; TAS:UniProtKB.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000270; OPR_PB1.
DR   InterPro; IPR015745; PKC.
DR   InterPro; IPR012233; PKC_zeta.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR002219; Prot_Kinase_C-like_PE/DAG-bd.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   PANTHER; PTHR22985:SF86; PKC; 1.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00564; PB1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000554; PKC_zeta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00666; PB1; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Complete proteome; Cytoplasm; Endosome;
KW   Kinase; Membrane; Metal-binding; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Proto-oncogene;
KW   Serine/threonine-protein kinase; Transferase; Tumor suppressor; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    596       Protein kinase C iota type.
FT                                /FTId=PRO_0000055710.
FT   DOMAIN       25    108       OPR.
FT   DOMAIN      254    522       Protein kinase.
FT   DOMAIN      523    594       AGC-kinase C-terminal.
FT   ZN_FING     140    190       Phorbol-ester/DAG-type.
FT   NP_BIND     260    268       ATP (By similarity).
FT   REGION        1    253       Regulatory domain.
FT   REGION        1     28       Required for interaction with RAB2.
FT   REGION       72     91       Interaction with PARD6A.
FT   ACT_SITE    378    378       Proton acceptor (By similarity).
FT   BINDING     283    283       ATP (By similarity).
FT   MOD_RES     265    265       Phosphotyrosine; by Src.
FT   MOD_RES     280    280       Phosphotyrosine; by Src.
FT   MOD_RES     334    334       Phosphotyrosine; by Src.
FT   MOD_RES     412    412       Phosphothreonine.
FT   MOD_RES     564    564       Phosphothreonine.
FT   VARIANT     118    118       P -> L (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_042322.
FT   VARIANT     130    130       R -> C.
FT                                /FTId=VAR_042323.
FT   MUTAGEN      29     29       K->A: No effect on interaction with
FT                                SQSTM1.
FT   MUTAGEN      72     72       D->A: Loss of interaction with PARD6A and
FT                                with SQSTM1.
FT   MUTAGEN      85     85       E->A: Slight decrease of interaction with
FT                                PARD6A. Loss of interaction with PARD6A;
FT                                when associated with A-91.
FT   MUTAGEN      91     91       R->A: Slight decrease of interaction with
FT                                PARD6A. Loss of interaction with PARD6A;
FT                                when associated with A-85.
FT   MUTAGEN     265    265       Y->F: No effect on the Src-mediated
FT                                phosphorylation state. No effect on Src-
FT                                induced enzyme activity. Little effect on
FT                                TRAF6-mediated activation of NF-kappa-B.
FT                                Decreased binding to KPNB1/importin-beta.
FT   MUTAGEN     280    280       Y->F: No effect on the Src-mediated
FT                                phosphorylation state. No effect on Src-
FT                                induced enzyme activity. No effect on
FT                                TRAF6-mediated activation of NF-kappa-B.
FT   MUTAGEN     334    334       Y->F: No effect on the Src-mediated
FT                                phosphorylation state. Significant
FT                                reduction of Src-induced enzyme activity.
FT                                Greatly reduced TRAF6-mediated activation
FT                                of NF-kappa-B. Reduces NGF-dependent cell
FT                                survival.
FT   CONFLICT    485    485       L -> M (in Ref. 3; AAH22016).
FT   CONFLICT    508    508       H -> L (in Ref. 3; AAH22016).
FT   CONFLICT    560    560       P -> R (in Ref. 3; AAH22016).
FT   STRAND       26     32
FT   STRAND       35     41
FT   HELIX        47     57
FT   STRAND       67     71
FT   STRAND       77     79
FT   HELIX        83     95
FT   STRAND      101    106
FT   STRAND      254    262
FT   STRAND      264    273
FT   TURN        274    276
FT   STRAND      279    286
FT   HELIX       287    289
FT   TURN        293    295
FT   HELIX       296    306
FT   TURN        307    310
FT   STRAND      318    321
FT   STRAND      325    333
FT   HELIX       340    345
FT   HELIX       352    371
FT   HELIX       381    383
FT   STRAND      384    386
FT   STRAND      392    394
FT   HELIX       417    419
FT   HELIX       422    425
FT   HELIX       433    448
FT   HELIX       466    476
FT   HELIX       487    496
FT   STRAND      499    501
FT   TURN        505    507
FT   TURN        509    511
FT   HELIX       512    518
FT   HELIX       520    522
FT   HELIX       527    530
FT   TURN        531    533
FT   HELIX       568    571
FT   HELIX       577    579
SQ   SEQUENCE   596 AA;  68262 MW;  1E3F8C1D4BFC734F CRC64;
     MPTQRDSSTM SHTVAGGGSG DHSHQVRVKA YYRGDIMITH FEPSISFEGL CNEVRDMCSF
     DNEQLFTMKW IDEEGDPCTV SSQLELEEAF RLYELNKDSE LLIHVFPCVP ERPGMPCPGE
     DKSIYRRGAR RWRKLYCANG HTFQAKRFNR RAHCAICTDR IWGLGRQGYK CINCKLLVHK
     KCHKLVTIEC GRHSLPQEPV MPMDQSSMHS DHAQTVIPYN PSSHESLDQV GEEKEAMNTR
     ESGKASSSLG LQDFDLLRVI GRGSYAKVLL VRLKKTDRIY AMKVVKKELV NDDEDIDWVQ
     TEKHVFEQAS NHPFLVGLHS CFQTESRLFF VIEYVNGGDL MFHMQRQRKL PEEHARFYSA
     EISLALNYLH ERGIIYRDLK LDNVLLDSEG HIKLTDYGMC KEGLRPGDTT STFCGTPNYI
     APEILRGEDY GFSVDWWALG VLMFEMMAGR SPFDIVGSSD NPDQNTEDYL FQVILEKQIR
     IPRSLSVKAA SVLKSFLNKD PKERLGCHPQ TGFADIQGHP FFRNVDWDMM EQKQVVPPFK
     PNISGEFGLD NFDSQFTNEP VQLTPDDDDI VRKIDQSEFE GFEYINPLLM SAEECV
//
